Literature DB >> 21499887

Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status.

Javier de Miguel-Díez1, Pilar Carrasco-Garrido, Javier Rejas-Gutierrez, Antonio Martín-Centeno, Elena Gobartt-Vázquez, Valentín Hernandez-Barrera, Miguel Angel Gil de, Rodrigo Jimenez-Garcia.   

Abstract

The aim of this study was to evaluate the relationship between inappropriate overuse of inhaled corticosteroids and self-reported health status and the annual cost of patients with stable chronic obstructive pulmonary disease (COPD) recruited in the primary-care setting. An observational, crossover, descriptive study was conducted. Patients with stable COPD and aged ≥40 years, evaluated in primary care, were included. Data collected were demographic variables, clinical characteristics, self-reported health status (SF-12), the severity of the illness, treatment, and health-care resource utilization in the past year. The patients were recruited during a period of 3 months (from January 1 to March 31, 2003). Use was considered inappropriate when corticosteroids were prescribed by physicians for patients not meeting criteria for its use as recommended in guidelines. A total of 10,711 patients [75.6% males; mean age = 67.1 (SD = 9.66) years] were evaluated. Disease severity was mild in 35.5% of the cases, moderate in 53.4%, and severe in 11.2%. Among them, 3,697 (34.5%) subjects were prescribed inhaled corticosteroids or drug combinations containing such therapies, with a rate of inappropriate use of 18.2%. Physical health status was significantly lower among patients showing inappropriate corticosteroids use: 37.35 (SD = 9.53) vs. 40.7 (SD = 9.80) (p < 0.05). The annual cost per patient of COPD management was significantly higher in the group with inappropriate inhaled corticosteroids use: <euro>1,590 (SD = 1,834) vs. <euro>1,157 (SD = 1,536) (p < 0.05). Factors statistically associated with inappropriate use of corticosteroids were educational attainment [OR: 2.77 (95% CI: 1.36-5.63) for nonuniversity training], a history of heart disease [OR: 1.42 (95% CI: 1.02-1.97)], depression [OR: 1.47 (95% CI: 1.05-2.05)], any allergy [OR 1.69 (95% CI: 1.13-2.54)], and physical health status [OR 0.97 (95% CI: 0.96-0.98)]. Lack of adherence to the recommended criteria for using inhaled corticosteroids therapy in the management of COPD patients was associated with lower self-reported health status and higher costs. Factors statistically associated with inappropriate use of corticosteroids were educational attainment, a history of heart disease, depression, any allergy, and physical health status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499887     DOI: 10.1007/s00408-011-9289-0

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  28 in total

Review 1.  [Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease].

Authors:  J A Barberà; G Peces-Barba; A G Agustí; J L Izquierdo; E Monsó; T Montemayor; J L Viejo
Journal:  Arch Bronconeumol       Date:  2001-06       Impact factor: 4.872

2.  National survey of guideline-compliant COPD management among pneumologists and primary care physicians.

Authors:  Thomas Glaab; Norbert Banik; Olivier T Rutschmann; Marion Wencker
Journal:  COPD       Date:  2006-08       Impact factor: 2.409

3.  [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipúzcoa].

Authors:  L Marco Jordán; J C Martín Berra; M Corres Iñigo; R Luque Díez; G Zubillaga Garmendia
Journal:  Arch Bronconeumol       Date:  1998-01       Impact factor: 4.872

Review 4.  Suboptimal medical therapy in COPD: exploring the causes and consequences.

Authors:  S D Ramsey
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

5.  Antibiotics and steroids for exacerbations of COPD in primary care: compliance with Dutch guidelines.

Authors:  Berendina M Roede; Patrick Je Bindels; Henk J Brouwer; Paul Bresser; Corianne Ajm de Borgie; Jan M Prins
Journal:  Br J Gen Pract       Date:  2006-09       Impact factor: 5.386

6.  Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease.

Authors:  José Luis Izquierdo-Alonso; J de Miguel-Díez
Journal:  COPD       Date:  2004       Impact factor: 2.409

7.  International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.

Authors:  A Sonia Buist; Mary Ann McBurnie; William M Vollmer; Suzanne Gillespie; Peter Burney; David M Mannino; Ana M B Menezes; Sean D Sullivan; Todd A Lee; Kevin B Weiss; Robert L Jensen; Guy B Marks; Amund Gulsvik; Ewa Nizankowska-Mogilnicka
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

Review 8.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Sonal Singh; Aman V Amin; Yoon K Loke
Journal:  Arch Intern Med       Date:  2009-02-09

9.  Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study.

Authors:  Pilar Carrasco Garrido; Javier de Miguel Díez; Javier Rejas Gutiérrez; Antonio Martín Centeno; Elena Gobartt Vázquez; Angel Gil de Miguel; Marta García Carballo; Rodrigo Jiménez García
Journal:  Health Qual Life Outcomes       Date:  2006-05-23       Impact factor: 3.186

10.  Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD.

Authors:  Elisabeth Ståhl; Sven-Arne Jansson; Ann-Christin Jonsson; Klas Svensson; Bo Lundbäck; Fredrik Andersson
Journal:  Health Qual Life Outcomes       Date:  2003-06-02       Impact factor: 3.186

View more
  21 in total

1.  GOLD Stage and Treatment in COPD: A 500 Patient Point Prevalence Study.

Authors:  Katherine A Safka; Joshua Wald; Hongyu Wang; Luke McIvor; Andrew McIvor
Journal:  Chronic Obstr Pulm Dis       Date:  2016-12-22

Review 2.  Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Authors:  Gerard J Criner; Jean Bourbeau; Rebecca L Diekemper; Daniel R Ouellette; Donna Goodridge; Paul Hernandez; Kristen Curren; Meyer S Balter; Mohit Bhutani; Pat G Camp; Bartolome R Celli; Gail Dechman; Mark T Dransfield; Stanley B Fiel; Marilyn G Foreman; Nicola A Hanania; Belinda K Ireland; Nathaniel Marchetti; Darcy D Marciniuk; Richard A Mularski; Joseph Ornelas; Jeremy D Road; Michael K Stickland
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

3.  A Social Return on Investment Analysis of Improving the Management of Chronic Obstructive Pulmonary Disease Within the Spanish National Healthcare System.

Authors:  María Merino; Teresa Martín Lorenzo; Paulina Maravilla-Herrera; Julio Ancochea; José Tomás Gómez Sáenz; Nicole Hass; Jesús Molina; Germán Peces-Barba; Marta Trapero-Bertran; Juan Antonio Trigueros Carrero; Álvaro Hidalgo-Vega
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-21

4.  Systematic overuse of healthcare services: a conceptual model.

Authors:  Najlla Nassery; Jodi B Segal; Eva Chang; John F P Bridges
Journal:  Appl Health Econ Health Policy       Date:  2015-02       Impact factor: 2.561

5.  Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.

Authors:  Barbara P Yawn; Yunfeng Li; Haijun Tian; Jie Zhang; Steve Arcona; Kristijan H Kahler
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-06-27

6.  Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.

Authors:  Anand A Dalal; Manan Shah; Anna O D'Souza; Sham Chaudhari; Glenn Crater
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-01-18

7.  Guideline based knowledge and practice of physicians in the management of COPD in a low- to middle-income country.

Authors:  Suraj Ghimire; Anish Lamichhane; Anita Basnet; Samiksha Pandey; Nahakul Poudel; Bhushan Shrestha; Santosh Pathak; Gaurav Mahato; Ram Kumar Shrestha
Journal:  Clin Respir J       Date:  2022-01-13       Impact factor: 1.761

8.  Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort.

Authors:  Yu-Feng Wei; Ping-Hung Kuo; Ying-Huang Tsai; Chi-Wei Tao; Shih-Lung Cheng; Chao-Hsien Lee; Yao-Kuang Wu; Ning-Hung Chen; Wu-Huei Hsu; Jeng-Yuan Hsu; Ming-Shian Lin; Chin-Chou Wang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-14

9.  Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol.

Authors:  Job F M van Boven; Miguel Román-Rodríguez; Janwillem W H Kocks; Joan B Soriano; Maarten J Postma; Thys van der Molen
Journal:  NPJ Prim Care Respir Med       Date:  2015-08-06       Impact factor: 2.871

10.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

Authors:  Guy Brusselle; David Price; Kevin Gruffydd-Jones; Marc Miravitlles; Dorothy L Keininger; Rebecca Stewart; Michael Baldwin; Rupert C Jones
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.